Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1989 8
1990 3
1991 11
1992 3
1993 5
1994 7
1995 6
1997 5
1998 7
1999 5
2000 9
2001 1
2002 7
2003 11
2004 9
2005 22
2006 27
2007 14
2008 15
2009 12
2010 13
2011 18
2012 13
2013 21
2014 23
2015 27
2016 26
2017 31
2018 38
2019 38
2020 44
2021 56
2022 42
2023 61
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

588 results

Results by year

Filters applied: . Clear all
Page 1
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Ascierto PA, et al. Among authors: giannarelli d. J Clin Oncol. 2023 Jan 10;41(2):212-221. doi: 10.1200/JCO.21.02961. Epub 2022 Sep 1. J Clin Oncol. 2023. PMID: 36049147 Clinical Trial.
Reply by Authors.
Mastroianni R, Ferriero M, Tuderti G, Anceschi U, Bove AM, Brassetti A, Misuraca L, Zampa A, Torregiani G, Ghiani E, Giannarelli D, Guaglianone S, Gallucci M, Simone G. Mastroianni R, et al. Among authors: giannarelli d. J Urol. 2022 May;207(5):992. doi: 10.1097/JU.0000000000002422.02. Epub 2022 Feb 18. J Urol. 2022. PMID: 35176866 No abstract available.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. Among authors: giannarelli d. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao MG, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Dummer R, Sileni VC, Palmieri G. Ascierto PA, et al. Among authors: giannarelli d. Nat Commun. 2024 Jan 2;15(1):146. doi: 10.1038/s41467-023-44475-6. Nat Commun. 2024. PMID: 38167503 Free PMC article. Clinical Trial.
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.
Anpalakhan S, Signori A, Cortellini A, Verzoni E, Giusti R, Aprile G, Ermacora P, Catino A, Pipitone S, Di Napoli M, Scotti V, Mazzoni F, Guglielmini PF, Veccia A, Maruzzo M, Schinzari G, Casadei C, Grossi F, Rizzo M, Montesarchio V, Verderame F, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Tondini CA, Camerini A, Banzi MC, Sorarù M, Zucali PA, Vignani F, Ricciardi S, Russo A, Cosenza A, Di Maio M, De Giorgi U, Pignata S, Giannarelli D, Pinto C, Buti S, Fornarini G, Rebuzzi SE, Rescigno P, Addeo A, Banna GL, Bersanelli M. Anpalakhan S, et al. Among authors: giannarelli d. iScience. 2023 Sep 22;26(11):107970. doi: 10.1016/j.isci.2023.107970. eCollection 2023 Nov 17. iScience. 2023. PMID: 37860695 Free PMC article.
Validation of Esaso Classification of Diabetic Maculopathy.
Panozzo G, Franzolin E, Giannarelli D, Dalla Mura G, Longo R, Cicinelli MV; ESASO Study Group. Panozzo G, et al. Among authors: giannarelli d. Eur J Ophthalmol. 2024 Mar;34(2):497-501. doi: 10.1177/11206721231186649. Epub 2023 Jul 16. Eur J Ophthalmol. 2024. PMID: 37455446
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.
Ferrara MG, Belluomini L, Smimmo A, Sposito M, Avancini A, Giannarelli D, Milella M, Pilotto S, Bria E. Ferrara MG, et al. Among authors: giannarelli d. Crit Rev Oncol Hematol. 2023 Apr;184:103929. doi: 10.1016/j.critrevonc.2023.103929. Epub 2023 Feb 10. Crit Rev Oncol Hematol. 2023. PMID: 36773668 Free article. Review.
Cost-effectiveness in transient hypocalcemia post-thyroidectomy.
Mercante G, Anelli A, Giannarelli D, Giordano D, Sinopoli I, Ferreli F, Digiesi G, Appetecchia ML, Barnabei A, Cristalli G, Conti L, Pellini R, Piazza F, Lombardi D, De Virgilio A, Spriano G. Mercante G, et al. Among authors: giannarelli d. Head Neck. 2019 Nov;41(11):3940-3947. doi: 10.1002/hed.25934. Epub 2019 Aug 31. Head Neck. 2019. PMID: 31472003 Clinical Trial.
Do immune checkpoint inhibitors need new studies methodology?
Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E. Ferrara R, et al. Among authors: giannarelli d. J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131. J Thorac Dis. 2018. PMID: 29951307 Free PMC article. Review.
588 results